Recro Pharma Inc (NASDAQ:REPH) has earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.50.
A number of equities analysts recently commented on REPH shares. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research note on Wednesday, November 15th. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research note on Friday, October 27th. Finally, Oppenheimer started coverage on Recro Pharma in a research note on Tuesday. They set a “buy” rating and a $19.00 price target for the company.
In other news, major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $9.58, for a total value of $2,132,661.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the sale, the insider now directly owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The disclosure for this sale can be found here. Insiders sold a total of 860,414 shares of company stock valued at $8,289,916 over the last ninety days. Corporate insiders own 21.60% of the company’s stock.
Shares of Recro Pharma (NASDAQ REPH) traded up $0.12 during trading on Tuesday, reaching $8.21. The company had a trading volume of 47,792 shares, compared to its average volume of 114,843. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.59. The company has a market capitalization of $157.01, a price-to-earnings ratio of -3.82 and a beta of -0.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/recro-pharma-inc-reph-given-average-rating-of-buy-by-brokerages.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.